<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>CD73 inhibitors present significant opportunities in cancer immunotherapy by reversing immunosuppression in tumors and enhancing immune response. Novel antibodies, RNA, and small molecules are in development, showing potential especially in combination therapies and in facilitating better diagnosis and treatment through advanced imaging.Dublin, May 14, 2026 (GLOBE NEWSWIRE) -- The <a href="https://www.researchandmarkets.com/reports/6179391/pipeline-cd73-inhibitors?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=bspchc&amp;utm_campaign=2252499+-+CD73+Inhibitors+Pipeline+Competitor+Analysis+Report+2026%3a+Active+R%26D+Programs+by+R%26D+Phase+and+Profile+of+Inhibitors+by+Drug+Modality&amp;utm_exec=chdomspi" rel="nofollow" target="_blank" title="Pipeline of CD73 Inhibitors">"Pipeline of CD73 Inhibitors"</a> report has been added to ResearchAndMarkets.com's offering. This competitive intelligence report about CD73 Inhibitors provides an up-to-date competitor evaluation in the field of antibodies, RNA and small molecules in research and development inhibiting CD73. This report will be prepared on demand within one working day upon order placement. The report lists active CD73 inhibitor R&amp;D programs by R&amp;D phase in a tabular format and describes in brief the profile of CD73 inhibitors by drug modality. CD73 (5'-nucleotidase or NT5E) is a cell surface enzyme which catalyzes the extracellular hydrolysis of adenosine monophosphate (AMP) to produce anti-inflammatory and immunosuppressive adenosine. Immunosupressive adenosine contributes to immune evasion in solid tumors by accumulating within the tumor microenvironment and thereby inhibiting immune effector cells (e.g., CD8+ T cells). As a novel checkpoint protein, CD73 is overexpressed in the immune system of various tumors, where adenosine is abundantly enriched. CD73 expression levels correlate with a worse prognosis in specific cancer types, including breast cancer. Adenosine production via CD73 can be therapeutically inhibited by two independent mechanisms: (1) enzyme inhibition, and (2) receptor internalization and subsequent degradation. The reduction of adenosine restores immune function. Once the immunosuppressive effects of adenosine are removed, activation of antitumor immune cells may be restored resulting in tumor cell death. A large number of monoclonal antibodies (mAbs), nucleotides, and non-nucleotides as potent CD73 inhibitors are being discovered, providing opportunities for novel tumor immunotherapy. CD73 inhibitors in clinical trials show promising results in combination therapy for various solid tumors. The development of CD73-specific companion positron emission tomography imaging ligands holds potential for facilitating diagnosis, patient selection, and treatment efficacy evaluation throughout the entire process of CD73-targeted therapeutic development. For more information about this report visit <a href="https://www.researchandmarkets.com/reports/6179391/pipeline-cd73-inhibitors?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=bspchc&amp;utm_campaign=2252499+-+CD73+Inhibitors+Pipeline+Competitor+Analysis+Report+2026%3a+Active+R%26D+Programs+by+R%26D+Phase+and+Profile+of+Inhibitors+by+Drug+Modality&amp;utm_exec=chdomspi" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/9rfimn</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/NDYxOWFhNDAtZTAyYy00NmRlLWJlZmMtYjllMDM4M2RiMjZjLTEwMjY3MzctMjAyNi0wNS0xNC1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

CD73 Inhibitors Pipeline Competitor Analysis Report 2026: Active R&D Programs by R&D Phase and Profile of Inhibitors by Drug Modality

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn